Compare ULCC & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ULCC | MLTX |
|---|---|---|
| Founded | 1994 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2021 | N/A |
| Metric | ULCC | MLTX |
|---|---|---|
| Price | $5.36 | $15.80 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 9 |
| Target Price | $5.67 | ★ $22.22 |
| AVG Volume (30 Days) | ★ 3.7M | 1.2M |
| Earning Date | 02-11-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,724,000,000.00 | N/A |
| Revenue This Year | $18.37 | N/A |
| Revenue Next Year | $12.30 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.89 | $5.95 |
| 52 Week High | $9.58 | $62.75 |
| Indicator | ULCC | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.12 | 52.61 |
| Support Level | $4.93 | $15.27 |
| Resistance Level | $6.49 | $16.15 |
| Average True Range (ATR) | 0.50 | 0.74 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 35.47 | 58.69 |
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.